| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Huafang Li, Jianfeng Luo, Chuanyue Wang, Shiping Xie, Xiufeng Xu, Xiaoping Wang, Wenjuan Yu, Niufan Gu, John M Kan. Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial. Schizophrenia research. vol 157. issue 1-3. 2015-02-26. PMID:24994555. |
antipsychotics, such as aripiprazole and risperidone, are often used to treat individuals with schizophrenia. |
2015-02-26 |
2023-08-13 |
human |
| Huafang Li, Jianfeng Luo, Chuanyue Wang, Shiping Xie, Xiufeng Xu, Xiaoping Wang, Wenjuan Yu, Niufan Gu, John M Kan. Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial. Schizophrenia research. vol 157. issue 1-3. 2015-02-26. PMID:24994555. |
the objective of this study is to investigate the efficacy, safety, and tolerability of aripiprazole and risperidone in chinese han schizophrenia subjects in mainland china. |
2015-02-26 |
2023-08-13 |
human |
| Gagan Fervaha, Ofer Agid, Hiroyoshi Takeuchi, George Foussias, Gary Remingto. Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: findings from the NIMH CATIE study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 24. issue 7. 2015-02-12. PMID:24726579. |
data were drawn from the clinical antipsychotic trial of intervention effectiveness (catie) study, where participants with a dsm-iv diagnosis of schizophrenia were randomized to receive olanzapine, perphenazine, quetiapine, risperidone or ziprasidone under double-blind conditions (n=753). |
2015-02-12 |
2023-08-13 |
human |
| Hiroyoshi Takeuchi, Takefumi Suzuki, Robert R Bies, Gary Remington, Koichiro Watanabe, Masaru Mimura, Hiroyuki Uchid. Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study. The Journal of clinical psychiatry. vol 75. issue 11. 2015-02-09. PMID:25099201. |
dose reduction of risperidone and olanzapine and estimated dopamine d₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study. |
2015-02-09 |
2023-08-13 |
Not clear |
| Manabu Takaki, Yutaka Mizuki, Tomoko Mik. Blonanserin improved dystonia induced by risperidone or olanzapine in two patients with schizophrenia. The Journal of neuropsychiatry and clinical neurosciences. vol 26. issue 2. 2015-01-26. PMID:24763772. |
blonanserin improved dystonia induced by risperidone or olanzapine in two patients with schizophrenia. |
2015-01-26 |
2023-08-13 |
Not clear |
| Xueqin Song, Xue Li, Jinsong Gao, Jingping Zhao, Youhui Li, Xiaoduo Fan, Luxian L. APOA-I: a possible novel biomarker for metabolic side effects in first episode schizophrenia. PloS one. vol 9. issue 4. 2015-01-23. PMID:24710015. |
the purpose of this study was to investigate the change in plasma protein expression in first episode schizophrenia after an 8-week treatment with risperidone, and to explore potential biomarkers for metabolic side effects associated with risperidone treatment. |
2015-01-23 |
2023-08-13 |
Not clear |
| Xueqin Song, Xue Li, Jinsong Gao, Jingping Zhao, Youhui Li, Xiaoduo Fan, Luxian L. APOA-I: a possible novel biomarker for metabolic side effects in first episode schizophrenia. PloS one. vol 9. issue 4. 2015-01-23. PMID:24710015. |
using proteomic analysis, the study suggested that apoa-i might be a novel biomarkers related to metabolic side effects in first episode schizophrenia treated with risperidone. |
2015-01-23 |
2023-08-13 |
Not clear |
| W Wolfgang Fleischhacker, Srihari Gopal, Rosanne Lane, Cristiana Gassmann-Mayer, Pilar Lim, David Hough, Bart Remmerie, Marielle Eerdeken. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. The international journal of neuropsychopharmacology. vol 15. issue 1. 2015-01-22. PMID:21777507. |
a randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. |
2015-01-22 |
2023-08-12 |
Not clear |
| W Wolfgang Fleischhacker, Srihari Gopal, Rosanne Lane, Cristiana Gassmann-Mayer, Pilar Lim, David Hough, Bart Remmerie, Marielle Eerdeken. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. The international journal of neuropsychopharmacology. vol 15. issue 1. 2015-01-22. PMID:21777507. |
this 53-wk, phase-iii double-blind study was designed to assess the non-inferiority of pp to risperidone long-acting injectable (ris-lai) in schizophrenia treatment. |
2015-01-22 |
2023-08-12 |
Not clear |
| Rachel Hershenberg, Daniel F Gros, Olga Brawman-Mintze. Role of atypical antipsychotics in the treatment of generalized anxiety disorder. CNS drugs. vol 28. issue 6. 2015-01-22. PMID:24794100. |
atypical antipsychotics such as quetiapine, aripiprazole, olanzapine, and risperidone have been shown to be helpful in addressing a range of anxiety and depressive symptoms in individuals with schizophrenia and schizoaffective disorders, and have since been used in the treatment of a range of mood and anxiety disorders. |
2015-01-22 |
2023-08-13 |
human |
| Yasuhiro Matsuda, Sayaka Sato, Kazuhiko Iwata, Shunichi Furukawa, Norifumi Hatsuse, Yukako Watanabe, Nobuo Anzai, Toshifumi Kishimoto, Emi Ikebuch. Effects of risperidone and aripiprazole on neurocognitive rehabilitation for schizophrenia. Psychiatry and clinical neurosciences. vol 68. issue 6. 2015-01-20. PMID:24506576. |
effects of risperidone and aripiprazole on neurocognitive rehabilitation for schizophrenia. |
2015-01-20 |
2023-08-12 |
Not clear |
| Celine M Laffont, Roberto Gomeni, Bo Zheng, Christian Heidbreder, Paul J Fudala, Azmi F Nasse. Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment. Clinical pharmacokinetics. vol 53. issue 6. 2015-01-19. PMID:24464285. |
population pharmacokinetics and prediction of dopamine d2 receptor occupancy after multiple doses of rbp-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment. |
2015-01-19 |
2023-08-12 |
Not clear |
| Celine M Laffont, Roberto Gomeni, Bo Zheng, Christian Heidbreder, Paul J Fudala, Azmi F Nasse. Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment. Clinical pharmacokinetics. vol 53. issue 6. 2015-01-19. PMID:24464285. |
rbp-7000 is a long-acting formulation of risperidone administered once monthly via subcutaneous (sc) injections for the treatment of schizophrenia. |
2015-01-19 |
2023-08-12 |
Not clear |
| Xueqin Song, Xiaoduo Fan, Xue Li, Wei Zhang, Jinsong Gao, Jingping Zhao, Amy Harrington, Douglas Ziedonis, Luxian L. Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia. Psychopharmacology. vol 231. issue 2. 2015-01-12. PMID:24337064. |
changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia. |
2015-01-12 |
2023-08-12 |
Not clear |
| Xueqin Song, Xiaoduo Fan, Xue Li, Wei Zhang, Jinsong Gao, Jingping Zhao, Amy Harrington, Douglas Ziedonis, Luxian L. Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia. Psychopharmacology. vol 231. issue 2. 2015-01-12. PMID:24337064. |
the present study aimed to examine the changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia. |
2015-01-12 |
2023-08-12 |
Not clear |
| Mehdi Farokhnia, Maryam Sabzabadi, Hossein Pourmahmoud, Mohammad-Reza Khodaie-Ardakani, Seyed-Mohammad-Reza Hosseini, Habibeh Yekehtaz, Mina Tabrizi, Farzin Rezaei, Bahman Salehi, Shahin Akhondzade. A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. Psychopharmacology. vol 231. issue 3. 2015-01-07. PMID:24013610. |
a double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. |
2015-01-07 |
2023-08-12 |
Not clear |
| David H Adams, Bruce J Kinon, Simin Baygani, Brian A Millen, Isabella Velona, Sara Kollack-Walker, David P Wallin. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia. BMC psychiatry. vol 13. 2015-01-06. PMID:23694720. |
we compared the time to discontinuation due to lack of tolerability over 24 weeks in patients suffering from schizophrenia treated with pomaglumetad methionil (ly2140023 monohydrate, the prodrug of metabotropic glutamate 2/3 receptor agonist, ly404039) or standard of care (soc: olanzapine, risperidone, or aripiprazole). |
2015-01-06 |
2023-08-12 |
Not clear |
| Laura Lammers, Bree Zehm, Richard William. Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada. BMC psychiatry. vol 13. 2015-01-06. PMID:23718192. |
the objectives of the present study were to compare safety and outcomes in patients with schizophrenia initiated on risperidone long-acting injection (rlai) or first generation antipsychotic injections (fgai) at a mental health centre in british columbia. |
2015-01-06 |
2023-08-12 |
Not clear |
| Hong-tao Song, Xin-yang Sun, Liang Zhang, Lin Zhao, Zhong-min Guo, Hui-min Fan, Ai-fang Zhong, Wei Niu, Yun-hua Dai, Li-yi Zhang, Zheng Shi, Xiao-ping Liu, Jim L. A preliminary analysis of association between the down-regulation of microRNA-181b expression and symptomatology improvement in schizophrenia patients before and after antipsychotic treatment. Journal of psychiatric research. vol 54. 2014-12-30. PMID:24694668. |
a total of 20 schizophrenia patients absent of antipsychotics and 20 age-and gender-matched normal controls were enrolled, and tested for 9 schizophrenia-associated microrna (mir-30e, mir-34a, mir-181b, mir-195, mir-346, mir-432, mir-7, mir-132 and mir-212) expression levels in plasma using quantitative rt-pcr and for symptomatology improvement using positive and negative syndrome scale (panss) before and after treatment (olanzapine, quetiapine, ziprasidone and risperidone) for the patients only. |
2014-12-30 |
2023-08-13 |
human |
| Daniel Umbricht, Richard S E Keefe, Stephen Murray, David A Lowe, Richard Porter, George Garibaldi, Luca Santarell. A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 39. issue 7. 2014-12-29. PMID:24549101. |
this 8-week (week 1, inpatient; weeks 2-8, outpatient), double-blind, randomized study used measurement and treatment research to improve cognition in schizophrenia (matrics) guidelines to investigate the nicotinic α7 partial agonist rg3487 (formerly mem3454) in cias; 215 patients with chronic stable schizophrenia received placebo or rg3487 (5, 15, or 50 mg) added to ongoing treatment with risperidone, paliperidone, or aripiprazole. |
2014-12-29 |
2023-08-12 |
Not clear |